Naples medical device firm picks up $20M in funding

Naples medical device firm Catalyst OrthoScience has closed a $20 million equity and venture debt financing round with a trio of funding partners. 

The company, focused on shoulder replacement orthopedics, also announced it has surpassed 10,000 total shoulder arthroplasty procedures. 

The funding is from RC Capital, Mutual Capital Partners and Bridge Bank, the release states. The capital, in part, will be used to “expand its distribution channel, further invest in talent and training, launch new products and solidify its position as a leading innovator,“ the release states. 

Catalyst has made significant progress since its first case in 2016,” Catalyst CEO Carl O’Connell says. “Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes. At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants.”

Carter McNabb, Managing Partner at RC Capital, and Catalyst board member, adds in the statement:, “Catalyst is a unique company in a fast-growing sector. This funding will allow the company to further its mission to improve shoulder arthroplasty for surgeons and patients across the continuum of care.”

Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Dr. Steven Goldberg, who, the company says, saw the need to make shoulder replacements less invasive, with fewer complications and a more natural-feeling shoulder after surgery. The company says its “total shoulder systems offer precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue.” It has a growing portfolio of patents and pending patents.